NeuroSense Therapeutics L... (NRSN)
NeuroSense Therapeutics Statistics
Share Statistics
NeuroSense Therapeutics has 23.99M shares outstanding. The number of shares has increased by 28.78% in one year.
| Shares Outstanding | 23.99M |
| Shares Change (YoY) | 28.78% |
| Shares Change (QoQ) | 0.45% |
| Owned by Institutions (%) | 3.58% |
| Shares Floating | 16.52M |
| Failed to Deliver (FTD) Shares | 1.56K |
| FTD / Avg. Volume | 1.04% |
Short Selling Information
The latest short interest is 290.88K, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 290.88K |
| Short % of Shares Out | 1.25% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.83. NeuroSense Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -1.83 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.21 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-594.53K |
| Employee Count | 17 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -27.61% in the last 52 weeks. The beta is 1.34, so NeuroSense Therapeutics's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | -27.61% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 44.08 |
| Average Volume (20 Days) | 149.99K |
Income Statement
| Revenue | n/a |
| Gross Profit | -97K |
| Operating Income | -12.05M |
| Net Income | -10.11M |
| EBITDA | -10.63M |
| EBIT | -10.73M |
| Earnings Per Share (EPS) | -0.83 |
Balance Sheet
The company has 3.38M in cash and 73K in debt, giving a net cash position of 3.31M.
| Cash & Cash Equivalents | 3.38M |
| Total Debt | 73K |
| Net Cash | 3.31M |
| Retained Earnings | -36.66M |
| Total Assets | 4.58M |
| Working Capital | 2.41M |
Cash Flow
In the last 12 months, operating cash flow was -10.13M and capital expenditures -3K, giving a free cash flow of -10.14M.
| Operating Cash Flow | -10.13M |
| Capital Expenditures | -3K |
| Free Cash Flow | -10.14M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for NRSN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -10.51 |
| Piotroski F-Score | 2 |